Most of these trials, investigating novel therapeutic compounds targeting AML LSCs, are phase I or II trials; however, some compounds are already in phase III: CD123/CLL-1 CAR-T cells, Hh pathway inhibitor PF-913, and HDAC inhibitors pracinostat and panobinostat. Here, CLEC12A is linked to acute myeloid leukemia.